NOT-DA-15-077: Notice to Extend the Expiration Date of PAR-12-239 "Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R01)"

Notice to Extend the Expiration Date of PAR-12-239 "Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R01)"

Notice Number: NOT-DA-15-077

Key Dates
Release Date: August 7, 2015

Related Announcements
PAR-12-239

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

This Notice extends the expiration date for PAR-12-239 "Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R01)", by one funding cycle.

Current Expiration Date: September 8, 2015
New Expiration Date: January 8, 2016

All other aspects of this FOA remain the same.

Inquiries

Please direct all inquiries to:

Aidan Hampson PhD.
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-8039
Email: [email protected]